AP 23517
Latest Information Update: 07 Sep 2021
At a glance
- Originator ARIAD Pharmaceuticals
- Class Osteoporosis therapies; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Musculoskeletal disorders
Most Recent Events
- 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
- 12 Nov 2003 Discontinued - Preclinical for Musculoskeletal disorders in USA (unspecified route)
- 20 Mar 2003 Suspended - Preclinical for Musculoskeletal disorders in USA (unspecified route)